Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1849-1858

  Rakic, Jean Marie ^a   Leys, Anita ^b   Brié, Heidi ^c   Denhaerynck, Kris ^d   Pacheco, Christy ^d   Vancayzeele, Stefaan ^c   Hermans, Christine ^c   MacDonald, Karen ^d   Abraham, Ivo ^d,e  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Novartis Pharma   (Belgium)

^d Matrix45   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Age related macular degeneration; Neovascular macular degeneration; Quality of life; Ranibizumab; Visual acuity; Visual function

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB;

AGED; ARTICLE; CLINICAL PRACTICE; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84884409168     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S49385     Document Type: Article

References (29)

1. Augood C, Fletcher A, Bentham G, et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004;11(2):117-129.
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900-1901.
3. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
4. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-851.
5. Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med. 2010;363(17):1648-1655.
6. Jonasson F, Arnarsson A, Eiríksdottir G, et al. Prevalence of age-related macular degeneration in old persons: age, gene/environment Susceptibility Reykjavik Study. Ophthalmology. 2011;118(5):825-830.
7. Wong TY, Wong T, Chakravarthy U, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116-126.
8. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no 19. Ophthalmology. 2005;112(4):533-539.
9. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol. 2003;87(1):8-12.
10. Rovner BW, Casten RJ, Massof RW, Leiby BE, Tasman WS; Wills Eye AMD Study. Psychological and cognitive determinants of vision function in age-related macular degeneration. Arch Ophthalmol. 2011;129(7):885-890.
11. Stevenson MR, Hart PM, Montgomery AM, McCulloch DW, Chakravarthy U. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol. 2004;88(9):1125-1130.
12. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65. e5.
13. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
14. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-324. e1.
15. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58. e1.
16. Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol. 2011;249(5):631-632.
17. Rijksinstituut voor Ziekteen Invaliditeitsverzekering. Vergoed-baarheid van de specialiteit Lucentis. [Eligibility of the specialty Lucentis]. Available at: http://www.riziv.fgov.be/inami_prd/ssp/cns2/pages/MinisterialDecisionDet.asp?qs_SpcCod=00643937&qs_EffDat=20071101&qs_MdId=4852. Accessed on 22 July 2013. German.
18. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11):1496-1504.
19. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-1058.
20. Clemons TE, Chew EY, Bressler SB, McBee W; Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No 10. Arch Ophthalmol. 2003;121(2):211-217.
21. Orr P, Rentz AM, Margolis MK, et al. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(6): 3354-3359.
22. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629-3635.
23. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
24. Sharma S, Oliver-Fernandez A. Age-related macular degeneration and quality of life: how to interpret a research paper in health-related quality of life. Curr Opin Ophthalmol. 2004;15(3):227-231.
25. European Medicines Agency. European Public Assessment Report Lucentis. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed July 22, 2013.
26. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908. et al.
27. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Opthalmology. 2013;120(5):1046-56.
28. TNS Opinion and Social. Special Eurobarometer 332. Tobacco. Brussels, Belgium: European Commission; 2010. Available from: http://ec.europa.eu/health/tobacco/docs/ebs332_en.pdf. Accessed June 20, 2013.
29. LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes. Available from: http://clinicaltrials.gov/show/NCT01318941. Accessed 22 July 2013.